In ongoing clinic trials, the surface tumor antigens CD20 [71], CD30 [72], CD33 [73], CD123 [74, 75], CD38 [76], CD138 [77], Ig κ light chain and Lewis-Y [78], have been applied as CAR targets, providing a pool of target antigen candidates in cancer treatment, although their clinical outcome remains further determined [15, 78–85]. This evidence concerns the gene CD38 and neoplasm.